[{"id":"46a8f53b-14fc-45af-acc4-ccdbef9c6bcc","acronym":"RAIN","url":"https://clinicaltrials.gov/study/NCT03743350","created_at":"2021-01-18T18:20:06.877Z","updated_at":"2024-07-02T16:37:05.241Z","phase":"Phase 2","brief_title":"NSCLC Exon 20 or HER2-activating Mutations","source_id_and_acronym":"NCT03743350 - RAIN","lead_sponsor":"Rain Therapeutics, inc","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tarlox (tarloxotinib bromide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2018-11-16"}]